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Abstract
Fibromyalgia (FM) is the second most common rheumatologic disorder, affecting 5% of 
the world population, and has a serious effect on the quality of life of patients, as well as 
an economic impact through lost workdays. This pain syndrome is a common cause of 
chronic widespread pain and is characterized by reduced pressure pain thresholds with 
hyperalgesia and allodynia, nonrestorative sleep, fatigue, cognitive dysfunction, and 
mood disturbances. The pharmacological treatment strategies for FM include the use 
of antidepressants, calcium channel modulators, muscle relaxants, and analgesics but 
have shown limited efficacy and therapeutic adherence. Thus, researchers have been 
seeking potential substances (new chemical entities or through drug repositioning) 
that could be used for FM treatment. In this context, natural products (NPs) have been 
shown to be promising pharmacological tools due to the variety of their pharmacologi-
cal activity and the number of molecular sites available as possible active targets. Recent 
clinical and preclinical studies have been conducted to verify the possible applicability 
© 2018 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
Attribution L cense (http://creativecommons. /licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
of NPs such as essential oils (EOs), plants extracts, terpenes, sapogenins, and alkaloids 
in the treatment of FM. The results have shown that natural products have an analgesic 
effect in different animal models of FM, probably by activation of inhibitory descending 
pathways, such as the periaqueductal gray and rostroventromedial medulla. Natural 
products and their secondary metabolites could therefore be a promising source for FM 
management. However, translational studies that seek to validate the preclinical studies 
are scarce, incipient, and lacking an approach focused on the traditional pharmaceutical 
market.
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1. Introduction
Fibromyalgia (FM) is a painful syndrome caused by changes in the central nervous sys-
tem. This syndrome is chronic in nature and is present in about 5% of the world popu-
lation. Generalized musculoskeletal pain and changes in sensitivity, as well as fatigue 
in the absence of any organic disease, are presented as clinical aspects. Other important 
symptoms may manifest in patients with FM such as sleep disturbances and cognitive 
problems, as well as a variety of psychosomatic symptoms. Patients with FM often com-
plain of tingling, numbness, burning, cutaneous hyperalgesia, momentary pain attacks, 
and depression [1].
Pathophysiological factors are genetic predisposition, autonomic and emotional dysfunc-
tions, physical or environmental stresses, and neurohormonal and inflammatory dysfunc-
tions [2]. Besides that, ischemia and muscular microtraumas, which result in pain during 
and after exercise, can be considered favorable for the onset of pain in FM. Elvin et al. [3] 
studied 10 female fibromyalgic patients and 11 female patients in the control group, using 
Doppler ultrasound in the infraspinatus muscle during low-intensity exercise. Experimental 
patients presented muscle ischemia when compared to control patients, perhaps because 
they evoked reflexes in the muscular sympathetic nervous activity, resulting in vasocon-
striction. This may be contributed to pain in FM, which could be resulting from possible 
microtraumas. An abrupt increase in muscle vascularization during and after dynamic 
exercise was also observed for patients with FM, which did not occur with static exercise 
when compared to the control patients. Thus, increased muscle sympathetic nerve activity 
in the FM group may have resulted in imbalance between vasodilation and sympathetic 
vasoconstriction.
Areas of the descending pathway of pain, such as the periaqueductal gray (PAG) and ros-
troventromedial area (RVM), which have mainly opioid and serotonergic activation, respec-
tively, may act in endogenous analgesia. These two areas make connections with the dorsal 
horn of the spinal cord, modulating the transmission of nociceptive messages [3, 4]. Changes 
in these areas of the central nervous system (CNS) probably occur due to a neurochemi-
cal imbalance, with the glutamatergic, 5-HTergic and opioidergic systems being important 
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targets to control this neurotransmitter fluidity. This results in the classification of FM as 
a central pain syndrome, also known as “dysfunctional pain,” where there are changes in 
sensitivity such as allodynia (pain due to a stimulus that normally does not cause pain) and 
hyperalgesia (increased pain of a stimulus that usually causes pain), without any tissue or 
nervous injury [5–7].
Due to the complexity of its pathophysiology, the treatment of FM is very difficult. Only 
30% of the medicines used to treat FM have some positive effect. Some drugs have high costs 
(financial or in terms of side effects), being possible triggers of collateral effects such as nausea, 
edema, tachycardia, and with poor therapeutic efficacy [1, 2, 8–12]. In order to better under-
stand the physiopathology as well as to investigate new treatment options for FM, animal 
models have been developed that mimic some symptoms of this syndrome. Scientists have 
used a combination of repetitive stimuli applied to the muscle, coupled with stress added to 
the nociceptive stimuli applied in the muscle to trigger lasting hyperalgesia, which mimics 
FM (Table 1) [13–16].
In the search for new sources of more effective drugs with fewer side effects, scientists have 
been focusing on the study of different pharmacological approaches including natural prod-
ucts (NPs) due to their promising effects on the CNS. NPs are considered the main source of 
new chemical entities in the search for new medicines and may be fundamental to the discov-
ery of new drugs for diseases or syndromes that still do not respond adequately to the current 
available treatments. In this context, an important approach to discover new painkillers has 
been developed with NPs such as medicinal plants or their secondary metabolites that could 
modulate painful conditions, including FM [17].
Medicinal plants (MPs) are natural products that have been used in the control of several 
diseases by the world’s population for thousands of years. Popular knowledge about 
the use of these plants has directed scientists to conduct new research seeking drugs 
that act on specific targets or multiple molecular sites such as the pathophysiology of 
FM usually presents [18, 19]. Many drugs that are commonly used in clinical treatment 
are derived directly or indirectly from MPs and include analgesics such as aspirin (anti-
inflammatory nonsteroidal derived from salicylic acid, which was initially extracted from 
Salix alba) and morphine (opioid analgesic derived from Papaver somniferum) [20]. As evi-
dence of the importance of natural products, between 2005 and 2010, the Food and Drug 
Administration (FDA) and the European Medicines Agency (EMA) approved 19 medi-
cines derived from NPs, including trabectedin (Yondelis™) and cannabidiol (Sativex®), 
for cancer and pain treatment, respectively [21, 22]. Moreover, the growing number of 
patents to protect new formulations containing NPs demonstrates the importance of these 
compounds [23].
In relation to FM, some classes of bioactive compounds extracted from medicinal plants have 
presented analgesic activity described in the literature, such as essential oils [24–26], extracts 
[27, 28], monoterpenes [29–31], sesquiterpenes [32], saponins [33], and alkaloids (Figure 1 and 
Table 2) [34].
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Author Animal model Induction Similarities with the 
clinical condition
Limitations of the model
Sluka, Kalra, 
Moore [35]
Acid saline-induced 
pain
Two injections of 
acid saline (pH 4; 
im) separated by 2–5 
days
Widespread 
and generalized 
hyperalgesia 
including the 
bilateral hind limbs, 
muscles, paws, and 
viscera, and anxiety
It is not clear if there are 
comorbidities such as 
depression, anxiety, fatigue, 
or sleep disturbances, 
as in FM. Unlike what is 
observed in FM, the model 
is sensitive to opioids 
intrathecally
Dina, Levine, 
Green [36]; 
Dina, Green, 
Levine [37]
Hyperalgesic priming 
model
An acute 
inflammatory insult 
(carrageenan or IL-6) 
followed by PGE2 
injection into the 
same muscle
Long duration of 
hyperalgesia may 
indicate differential 
processing of 
muscular or 
cutaneous pain by 
peripheral or central 
pathways
Pharmacological and non-
pharmacological treatments 
for FM or comorbidities, as 
well as changes in the CNS, 
have not yet been studied 
in this model
Yokoyama et 
al. [38]
Fatigue-enhanced 
muscle pain
Running wheel for 
2 h followed by two 
injections of acid 
saline (pH 5)
Muscle fatigue may 
increase hyperalgesia 
produced by low-
intensity agents
Pharmacological and 
non-pharmacological 
treatments for FM or 
comorbidities have not yet 
been determined
Nagakura et 
al. [39]
Biogenic amine 
depletion model
Repeated 
administration of 
reserpine (1 mg/kg/
day, for 3 consecutive 
days; sc)
Animals show signs 
of comorbidities 
as depression and 
anxiety
It is unclear how changes 
in the serotonergic 
system contribute 
to the maintenance 
of hyperalgesia. All 
studies so far have been 
performed only on males. 
It is not known if there are 
differences between males 
and females
Nishiyori et al. 
[40]
Cold stress model Maintenance in cold 
room (−3 to +4°C) 
overnight for 3 days 
and transfer between 
normal room 
temperature (24°C) 
and a cold room 
every 30 min during 
the day
Pharmacological 
treatments directed 
to FM also have an 
effect in this model, 
with the exception 
of opioids, which 
are not effective 
in FM and reduce 
hyperalgesia in the 
model cited
Comorbidities such as 
anxiety and depression are 
not developed
Khasar et al. 
[41]
Sound stress model Exposure to pure 
tones of 5, 11, 15, 
and 19 kHz, with 
amplitudes between 
20 and 110 dB in 
random times each 
minute, lasting from 
5 to 10 s, on days 1, 
3, and 4
Anxiety is developed 
as comorbidity
All studies so far have been 
performed only on males. 
It is not known if there are 
differences between males 
and females
Note: CNS, central nervous system; FM, fibromyalgia.
Table 1. Summary of major animal models of fibromyalgia.
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Natural product Dose/route Type of study Sample Molecular 
mechanism
References
Essential oils
Hyptis pectinata 0.3 ml/mouse 
(5%); sc
Preclinical Male Swiss mice 
(n = 8/group)
Opioid, 
serotoninergic, 
cholinergic, and 
reduction of SP, 
with involvement 
in the descending 
pain pathway
Quintans-Júnior 
et al. [24]
Ocimum basilicum 25, 50, and 100 
mg/kg; po
Preclinical Male Swiss mice 
(n = 8/group)
Opioid, 
glutamatergic, 
TRPV1, and 
reduction of SP, 
with involvement 
in the descending 
pain pathway
Nascimento et 
al. [25]
O24™ Not described; to Clinical 133 subjects of 
either sex
Stimulation of 
A-beta sensory 
fibers and 
inhibition of 
bradykinin, 
histamine, and 
prostaglandins
Ko et al. [26]
Figure 1. General structures of different categories of bioactive plant compounds studied for the treatment of FM: 
alkaloids (A1 and A2); monoterpenes (B); sesquiterpenes (C); and triterpenes, saponins, and steroids (D) (adapted from 
Azmir et al. [42]).
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Natural product Dose/route Type of study Sample Molecular 
mechanism
References
Plant extracts
Phyllanthus 
amarus and 
Phyllanthus 
fraternus
400 mg/kg; ip Preclinical Male Wistar rats 
(n = 5/group)
Opioid Chopade and 
Sayyad [27]
Ginkgo biloba 200 mg/day; po Clinical 25 subjects of 
either sex
Antioxidant Lister et al. [28]
Terpenes
Linalool 25 mg/kg; po Preclinical Male Swiss mice 
(n = 8/group)
Opioid, 
glutamatergic, 
and blocking 
of neuronal 
excitability
Nascimento et 
al. [29]
Citronellal 50 mg/kg; po Preclinical Male Swiss mice 
(n = 7/group)
Opioid, 
glutamatergic, 
SP pathway, 
TRPV1 receptor, 
involvement in 
the descending 
pain pathway, 
and blocking of 
sodium channels
Santos et al. [30]
α-Terpineol 25, 50, and 100 
mg/kg; po
Preclinical Male Swiss mice 
(n = 8/group)
Opioid, 
serotoninergic, 
glutamatergic, 
TRPV1, and 
reduction of SP, 
with involvement 
in the descending 
pain pathway
Oliveira et al. [31]
β-Caryophyllene 10 and 20 mg/
kg; po
Preclinical Male Swiss mice 
(n = 8/group)
Opioid and 
cannabinoid
Quintans-Júnior 
et al. [32]
Saponin
Hecogenin 
acetate
20 mg/kg; po Preclinical Male Swiss mice 
(n = 8/group)
Opioid, SP, 
ATP-sensitive K 
(+) channel, with 
involvement in 
the descending 
pain pathway
Quintans et al. 
[33]
Alkaloid
Capsaicin 0.075% (3 times/
day); to
Clinical 126 women and 
4 men
TRPV1 and 
reduction of SP
Casanueva et 
al. [34]
*All preclinical studies used the chronic muscle pain model induced by acid saline.
Note: ATP, adenosine triphosphate; ip, intraperitoneal; po, oral administration; sc, subcutaneous; SP, substance P; to, 
topically; TRPV1, transient receptor potential vanilloid 1.
Table 2. Summary of studies involving bioatctive compounds aimed at the treatment of fibromyalgia and their main 
mechanisms of action.
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2. Pharmacology of bioactive compounds
Bioactive compounds, produced by plants, are designated secondary metabolites. Metabolites 
can be divided into primary and secondary. Primary metabolites are those involved in growth 
and development, such as carbohydrates, amino acids, proteins, and lipids, while secondary 
metabolites, which often have unusual chemical structures, are not required for primary met-
abolic processes and are believed to support plant survival with respect to local challenges. 
Thus, the production of secondary metabolites of a given species will be related to their need 
for survival. Among the secondary metabolites, some compounds have an effect on biological 
systems, being considered bioactive, which defines them as secondary metabolites of plants 
that induce pharmacological or toxic effects in humans or animals [42].
Bioactive compounds can be extracted from various parts of the plant, such as the leaves, 
seeds, flowers, bark, roots, and fruits [43]. These compounds form the essential oil of the 
plant, resin, or other plant products, which can be extracted in a concentrated form (contain-
ing secondary metabolites) or by means of solvents, such as water, ethanol, methanol, chlo-
roform, dichloromethane, ether, and acetone [42]. The best solvent or extraction procedure 
will depend on the botanical material to be used as well as of the type of secondary metabo-
lites being obtained. In addition, various substances can be isolated from the essential oil or 
chemical extracts, such as terpenes, flavonoids, alkaloid, and steroids that already have some 
known property that can be used in the treatment of FM [43].
2.1. Essential oils
Essential oils (EOs) are derived from the secondary metabolism of aromatic plants and are 
mainly terpene compounds. They are volatile and usually have a strong and characteristic 
smell. In nature, they perform plant protection functions against predators and help attract 
certain animals for pollination. In industry, they are used for numerous purposes including 
in perfume, as antiseptics, and food preservatives but also have numerous pharmacological 
properties [44]. They are mixtures and may contain 20–60 compounds (or more) in varying 
concentrations. Usually, each EO is characterized by its major components, which may be 
number two or three and usually be between 20 and 70% of the oil [45].
Although the biological effect of EOs are thought to be due to the major components which 
define their pharmacological profiles, synergism between the molecules present in each oil, 
even those that are in a smaller quantity, can modulate the effects of the major components [45].
2.2. Plant extracts
Based on non-pharmacological studies and holistic or alternative medicine with the use of 
medicinal plants (and related products), several researchers have sought to evaluate the 
effects of materials obtained through NPs in clinical and preclinical studies. This research 
has been based on the popular and potentially dangerous belief given the chemical diversity 
of NPs that “what is natural, cannot do you harm.” The innovative pharmacological effects 
that these products are able to produce are promising but due to possible side effects remain 
challenging at the same time [50–52]. One way to evaluate possible pharmacological effects 
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and examine their use in folk medicine is to study plant extracts obtained through the use of 
several solvents [53–55]. The extraction of biological products using solvents is mainly used 
with fragile or delicate flower materials, which do not tolerate the heat of steam distillation. 
Examples of solvents which may be used to produce plant extracts are acetone, hexane, ether, 
methanol, or ethanol [43]. These extracts, in turn, can have a limited use due to their high vis-
cosity, facilitating aggregation and precipitation, or the presence of proteins that induce false 
results, causing better ways of obtaining and fractionating the crude extracts to be sought 
[54].
2.3. Terpenes
Terpenes are the largest group of secondary metabolites obtained through natural products, 
being made from isoprene units (five carbons (C5)). They exhibit a wide variety of structures 
and are the most common class of chemical compounds found in essential oils [43, 46–48]. 
Essential oils contain mainly monoterpenes (C10) and sesquiterpenes (C15), which are gener-
ally hydrocarbons of the general formula (C5H8)n. At a lower concentration, they are pres-
ent in essential oils as diterpenes (C20), triterpenes (C30), and tetraterpenes (C40), which 
are larger molecules. Terpenoids are oxygen compounds that can be derived from terpenes. 
These compounds may present predominantly as phenols, monoterpene alcohol, sesquiter-
pene alcohol, aldehydes, ketones, esters, oxides, lactones, and ethers [43].
Although monoterpenes are smaller molecules than sesquiterpenes, the structure and func-
tional properties of these groups are similar [43, 49]. Most monoterpenes are colorless, vola-
tile, and lipophilic, which promote greater penetration through the membrane [49]. Among 
the activities already described, the antinociceptive properties of these compounds have 
received a lot of attention [50–52].
2.4. Saponin
Triterpenoid or steroidal aglycones linked to portions of oligosaccharides are called saponins. 
Saponins are amphipathic because of the combination of the aglycone, having hydropho-
bic characteristics, and sugar molecules, with a hydrophilic profile. These compounds have 
been studied for use in the pharmaceutical, cosmetic, agronomic, and food industries [53]. 
Saponins present some therapeutic activities including powerful membrane-permeabilizing 
agents with hypocholesterolemic, immunostimulatory, anti-inflammatory, antimicrobial, 
anticarcinogenic, antiprotozoan, molluscicides, and antioxidant properties [54]. The majority 
of plant species-producing saponins are dicotyledonous and accumulate mainly triterpenoid 
saponins. The monocotyledon type mainly synthesizes saponins of the steroidal type [55].
2.5. Alkaloids
Alkaloids are complex compounds that contain nitrogen. These compounds have been used 
in the production of various drugs, such as metronidazole (derived from azomycin) and 
bedaquiline (derived from quinolone) [56–60]. Capsaicin is an alkaloid derived from hot chili 
peppers from the Capsicum. This alkaloid interacts with afferent nociceptors by means of the 
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vanilloid receptors, resulting in increased sensitivity, which is perceived as pruritus, stinging, 
or burning. This happens due to selective activation of type C afferent fibers, release of sub-
stance P, and cutaneous vasodilation. Capsaicin-based topical creams have been used in the 
treatment of painful disorders such as musculoskeletal or neuropathic disorders, probably 
functioning by depletion of substance P in the afferent nerve endings [34, 61–63].
3. Preclinical studies
Recently, Quintans-Júnior et al. [24] evaluated pretreatment with the EO from Hyptis pecti-
nata loaded in a nanoemulsion thermoreversible gel in an animal model of noninflammatory 
chronic muscular pain, an experimental model for FM. This pharmaceutical formulation con-
taining EO and Pluronic F127-based hydrogel produced a long-lasting and consistent anti-
hyperalgesic effect for 10 days after a single subcutaneous application, which was reversed 
by naloxone (opioid antagonist) and methysergide (serotoninergic antagonist). In addition, 
the formulation produced a significant reduction in substance P (SP) levels in the spinal cord. 
Moreover, it was also shown to increase neuron activation, by Fos protein expression, in the 
periaqueductal gray (PAG), the nucleus raphe magnus (NRM), and the locus coeruleus (LC), 
the CNS areas reported to be involved in the descending pathway of pain, so it appears that 
the formulation acts by improving the endogenous analgesia mechanism (Figure 3). Other 
studies have demonstrated that H. pectinata essential oil exhibits antinociceptive effects, prob-
ably mediated by the opioid and cholinergic receptors [64, 65].
Nascimento et al. [25] demonstrated in the same FM animal model that Ocimum basilicum 
essential oil, rich in monoterpenes such as linalool, has an important anti-hyperalgesic profile 
when complexed or noncomplexed with β-cyclodextrin (β-CD). Moreover, the complexed oil 
produced a long-lasting anti-hyperalgesic effect when compared to the oil alone, demonstrat-
ing that the complexation process allows greater stability and bioavailability of the oil or its 
main compounds, such as monoterpenes. In this paper, the authors also assessed Fos protein 
expression in the brains of mice and found that this oil promoted the activation of the PAG, 
NRM, and LC, which are encephalic regions that participate in the antinociceptive effect by 
the activation of the pain inhibitory descending pathway.
The results obtained for the O. basilicum essential oil may be due to its action on the inhibi-
tion of SP or through blocking the neurokinin-1 receptor and the vanilloid receptor (TRPV1). 
Indeed, this oil also acts by glutamatergic system inhibition or by the inhibition of inflam-
matory pathways, because it was able to produce a reduction in orofacial nociception when 
caused by formalin, capsaicin, and glutamate in mice [66]. Furthermore, when assessed using 
an electrophysiological approach, this oil was able to inhibit an orthodromic response in the 
dentate hippocampal gyrus, similar to DNQX (a glutamatergic drug), an AMPA and kainate 
receptor antagonist. In addition, another study carried out by Venâncio et al. [67] demon-
strated that the peripheral and central antinociceptive effects of O. basilicum essential oil are 
related to the inhibition of the biosynthesis of pain mediators, such as prostaglandins and 
prostacyclins, and its ability to interact with opioid receptors.
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Some studies using plant extracts for the treatment of FM have been performed. Chopade 
and Sayyad [27] used aqueous, methanolic, hydromethanolic, and hydroethanolic extracts of 
the genus Phyllanthus in an animal model of FM induced by acid saline. It was observed that 
the extract was able to reduce hyperalgesia without causing tolerance. Extracts of these plants 
have shown an antinociceptive effect, including in the hot-plate test [68]. In addition, there are 
indications these extracts depressed the CNS without apparently causing nervous toxicity or 
altering motor coordination, which may have corroborated with the anti-hyperalgesic effect 
obtained in the FM animal model [69].
The variability of the pharmacological mechanisms of terpenes and related compounds is 
shown in Figure 2, especially when incorporated into pharmaceutical formulations which 
improve their pharmacological properties. Moreover, β-caryophyllene, a major compound of 
H. pectinata leaf essential oil (HpEO), complexed with β-cyclodextrin decreased Fos protein 
expression in the superficial dorsal horn, which seems to involve the descending inhibitory 
pain system in an animal model of FM (Figure 2(C)). Germacrene D, another major component 
Figure 2. (A) Effect of nanoemulsion pharmaceutical formulation containing Hyptis pectinata leaf essential oil (NE-EOH; 
sc), tramadol (TRM, 10 mg/kg; ip), or vehicle (sc) on mechanical sensitivity induced by acidic saline in mice. Each point 
represents the mean ± SEM (n = 8, per group) of the ipsilateral paw withdrawal threshold. *p < 0.05 and **p < 0.01 
vs. control group (ANOVA followed by Tukey’s test). (B) Hydrophobic map of germacrene D (a major compound of 
Hyptis pectinata leaf essential oil) and μ-opioid receptor (μ-OR). Blue, hydrophobic region; red, hydrophilic region. (C) 
Fos-positive neurons in the lumbar spinal cord lamina I. Vehicle or β-caryophyllene-β-cyclodextrin (20 mg/kg) was 
administered orally, and, after 90 min, the animals were perfused (adapted from Quintans-Júnior et al. [25, 33]).
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of HpEO, has a strong interaction with the μ-opioid receptor (Figure 2(B)). A more interesting 
aspect was that when the HpEO was incorporated in a nanoemulsion thermoreversible plu-
ronic F127-based hydrogel, it produced a long-lasting and consistent anti-hyperalgesic effect 
(Figure 2(A)), suggesting that essential oils and their major components are promising tools 
for managing FM.
Some studies involving the effects of monoterpenes in FM experimental models have been 
undertaken due to their possible molecular effects on pain (Figure 3) [52]. Nascimento et al. 
[29] used linalool (Figure 4), a monoterpene present in plant species of the family Lamiaceae, 
complexed and noncomplexed in β-CD, in an animal model of FM and observed that both 
Figure 3. Schematic illustration of descending pain pathway and cyclodextrin complexation with monoterpenes 
(adapted from Quintans-Júnior et al. [24]).
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formulations had an anti-hyperalgesic effect, with the complexed form being more effective 
and producing a longer-lasting effect (for 24 h after administration). Previous studies have 
shown the analgesic effect of linalool on acute central nociception (hot plate), visceral (acetic 
acid) [70] and chronic pain models of neuropathic origin [71, 72], and the opioid and gluta-
matergic systems probably being involved in this action [73]. Moreover, linalool was able to 
reduce the action potential amplitude assessed using an isolated nerve in the single sucrose-
gap technique, showing it blocked neuronal excitability [74].
The possible benefits of the complexation of apolar compounds (such as terpenes) with CDs 
have been explored by the pharmaceutical industry and by researchers seeking improvements 
in pharmacological properties such as increased bioavailability, efficacy, and optimization of 
therapeutic doses (which reduces toxicity and adverse effects) [75, 76]. Clinical and preclini-
cal evidence has shown that the pharmacological effects of analgesic and anti-inflammatory 
drugs are improved when complexed with CDs [76–78].
Santos et al. [30] evaluated the effect of citronellal (Figure 4), a monoterpene present in Citrus 
and Cymbopogon plants, complexed in β-CD as a potential agent against FM symptoms. It was 
observed that complexation in CD improved the anti-hyperalgesic effect when compared to 
noncomplexed citronellal. This effect probably involves activation of descending pain path-
way areas, such as the PAG and rostroventromedial (RVM) areas, with possible interaction 
with the glutamate receptors, investigated by a docking study. Citronellal has already pre-
sented an antinociceptive effect on capsaicin, glutamate, and formalin-induced orofacial pain, 
showing that this terpene may be acting via SP and TRPV1 receptors or in the glutamatergic 
pathway [79]. In addition, the analgesic effect of citronellal was reversed by naloxone in hot-
plate tests, which strongly suggests its action on the opioid receptors and its ability to reduce 
neuronal excitability through blocking sodium channels [51, 79].
Another study, also using the chronic noninflammatory widespread pain model in mice (an 
FM animal model), evaluated the effect of α-terpineol (Figure 4), both pure and complexed in 
β-CD, as CDs are useful tools in improving the pharmacological properties of terpenes [77, 80]. 
The authors observed an anti-hyperalgesic effect, possibly related to the action of α-terpineol 
on the opioid and serotonergic receptors; visualized with the use of naloxone and ondanse-
tron antagonists; and confirmed by docking studies [31]. Similarly to citronellal, α-terpineol 
also showed antinociceptive effect in the capsaicin, glutamate, and formalin-induced orofacial 
Figure 4. Structure of terpenes studied for the treatment of FM (adapted from Guimarães et al. [23, 52]).
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nociception tests [81], indicating other possible mechanisms of action of this monoterpene. In 
summary, it has been shown that monoterpenes complexed in β-cyclodextrin reduce hyper-
algesia induced by chronic muscle pain, activating the descending pathway, as described in 
Figure 3.
Sesquiterpenes occur in nature as hydrocarbons or in oxygenated forms including lactones, 
alcohols, acids, aldehydes, and ketones. Biosynthesis of sesquiterpenes can occur by the 
mevalonic acid and the deoxyxylulose phosphate pathway. These compounds have various 
pharmacological activities including antileishmanial, antimalarial, antifungal, antibacterial, 
antiviral, anti-inflammatory, and antinociceptive properties and the ability to inhibit the pro-
duction of nitric oxide and eliminate hydroxyl radicals [82].
β-Caryophyllene (Figure 4) is a bicyclic sesquiterpene compound found in the EO of the 
Eugenia caryophyllata (cloves) and Piper nigrum (black pepper) plant species. In an experimen-
tal study conducted in an FM model in mice, this compound, complexed in β-CD, reduced 
primary and secondary hyperalgesia as well as inhibited the superficial dorsal horn of the 
spinal cord, possibly by activation of descending pain pathway [32]. Antagonism studies, in a 
capsaicin-induced nociception test, showed that the antinociceptive effect of β-caryophyllene 
was reversed by naloxone, β-funaltrexamine (a μ-opioid receptor antagonist), and AM630 (a 
CB2 receptor antagonist) [83]. In addition, in a neuropathic pain model, β-caryophyllene had 
an effect on thermal hyperalgesia and mechanical allodynia, reducing spinal neuroinflamma-
tion. The oral administration of β-caryophyllene was more effective than the subcutaneously 
injected synthetic CB2 agonist JWH-133 [84].
Quintans et al. [33] evaluated the effect of hecogenin acetate (HA), an acetylated steroidal sapo-
nin, complexed with β-CD in a chronic noninflammatory widespread pain model. Hecogenin 
is already used in the pharmaceutical industry to synthesize some oral contraceptive agents. 
The effect of noncomplexed or complexed HA caused an increase in the nociceptive threshold 
and primary and secondary hyperalgesia compared to the vehicle control group. However, 
the HA/β-CD complex was superior in producing an analgesic profile using lower nominal 
doses of the active principle (HA). In addition, the interaction of the HA with opioid receptors 
and a decrease in SP levels in the lumbar spinal cord were verified, which indicate participa-
tion of this substance in the descending inhibitory pain pathway [33, 85].
The antinociceptive effect of HA was previously observed in the tail-flick test. This effect 
was reversed by naloxone, CTOP (μ-opioid receptor antagonist), nor-BNI (κ-opioid receptor 
antagonist), naltrindole (δ-opioid receptor antagonist), and glibenclamide (ATP-sensitive K (+) 
channel blocker). Mice pretreated with HA had increased neuronal activation in the PAG area, 
suggesting the participation of the endogenous analgesia pathway in the hecogenin mecha-
nism of action [85].
Some clinical studies with EOs have been developed in humans with FM. O24™ is a blend of 
six essential oils: aloe vera, eucalyptus, lemon/orange, camphor, rosemary, and peppermint. 
This mixture is marketed for the relief of pain. In a double-blinded randomized clinical trial, 
Ko et al. [26] demonstrated the benefits of using this oil, topically, for FM pain relief. Males 
and females were recruited for the study through newspapers and internet communications. 
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FM diagnosis was confirmed before the patients enrolled in the study. The authors reveal 
that the main mode of action is as a counterirritant to the pain sensation. The mixture of oils 
promotes stimulation of A-beta sensory fibers, causing inhibition of the A-delta and C fibers. 
Moreover, the local effects of O24™ include the inhibition of bradykinin, histamine, and pros-
taglandins, which do not seem to be directly related to the analgesic effect in FM, so it is more 
reasonable to propose its effect indirectly in the pathways of pain modulation.
Rutledge and Jones [86] also investigated the topical effect of O24 in a double-blind randomized 
clinical trial associated with exercises multilevel for 12 weeks. Twenty patients with FM and 
23 patients of the sham group were submitted to the study. There was no statistical difference 
between the groups regarding the pain and physical function, but there was improvement of 
the physical function, without statistical difference, when compared before and after the treat-
ment, keeping the effect of O24 on the FM symptoms unknown. This result for O24 differs from 
that described by Ko et al. [26], which may result from the small sample and the type of exercise 
used, since some exercises may contribute to the maintenance of pain in patients with FM [3].
The effect of Ginkgo biloba extract and the coenzyme Q10 was evaluated in 23 fibromyalgic 
patients, before and after the treatment, by oral administration, for 12 weeks, with 64% of 
patients reporting an improvement in quality of life through the application of question-
naires. The improvement observed by these patients may be related in parts to the antioxidant 
activities described for both coenzyme Q10 and Ginkgo biloba [28].
Due to the properties attributed to capsaicin, Casanueva et al. [34] evaluated the short-term 
efficacy of topical capsaicin treatment in 130 patients with fibromyalgia who were already 
using drug therapy. Patients were randomly divided into a control group (same medical 
treatment that they received before randomization) and topical capsaicin group (medical 
treatment that they received before randomization + 0.075% capsaicin) by a computer-gener-
ated sequence. After 6 weeks, it was observed that the additional topical treatment reduced 
the myalgia score and improved the quality of life of these patients, showing that capsaicin 
was also effective in this syndrome.
4. Final considerations
Fibromyalgia is the second most common rheumatologic disorder, being characterized by 
the manifestation of widespread pain with sensory changes. The treatment strategies for the 
management of the FM include both pharmacological products (such as duloxetine, prega-
balina, and tramadol for pain and amitriptyline, cyclobenzaprine, and pregabalina for sleep 
disturbance) and non-pharmacological therapies (such as exercise and psychological thera-
pies) [87]. Despite this, fibromyalgia remains difficult to treat and is an important challenge 
for modern medicine, as the treatments for these conditions are still ineffective with a large 
number of side effects, making the search for new treatments ever more urgent.
In this context, one important approach to the discovery of new medicines with analge-
sic activity is research with natural products. For thousands of years, scientists and the 
pharmaceutical industry have used natural products as a source for new drugs or their 
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precursors, aimed at treating diseases or symptomatology that had no effective treatment. 
Despite of the animal models described for FM, some limitations can be observed, such as 
the reversion of the pain with opioid treatment and the absence of other signs and symp-
toms observed in humans. However, these models are the most resembled FM in humans, 
being tools used in the search for new treatment options. Nowadays, many natural sub-
stances have been studied, clinically and preclinically, for their analgesic potential with 
respect to fibromyalgia. In this context, essential oils, plant extracts, terpenes, and alkaloids 
are major sources of natural products.
These substances have been shown to have an analgesic effect in animal models of fibromyal-
gia, acting through different pathways, including activation of the descending inhibitory pain 
pathway—specifically the opioid, glutamatergic, cannabinoid, and serotoninergic systems; 
inhibition of SP in the superficial dorsal horn of the spinal cord; blockage of peripheral fibers; 
and antioxidant activity. In addition, clinical studies have shown the importance of NPs in the 
pain management of FM, improving their quality of life. The effective use of these products 
in the clinic, without reports of considerable adverse effects, describes the advances in the use 
of NPs in the treatment of FM. These finding make natural products a promising source of 
treatments for the management of chronic pain.
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